About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 413767, 6 pages
http://dx.doi.org/10.1155/2012/413767
Review Article

Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease

1Department of Dermatopathology, University Hospital of Liège, 4000 Liège, Belgium
2San Gallicano Dermatological Institute, 00144 Roma, Italy
3Department of Dermatology, Regional Hospital Citadelle, 4000 Liège, Belgium
4Department of Dermatology, Regional Hospital of Huy, 4500 Huy, Belgium

Received 30 April 2012; Accepted 1 August 2012

Academic Editor: Philippe Humbert

Copyright © 2012 Trinh Hermanns-Lê et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. E. Piérard, C. Piérard-Franchimont, G. Szepetiuk, P. Paquet, and P. Quatresooz, “The therapeutic potential of TNF-α antagonists for skin psoriasis comorbidities,” Expert Opinion on Biological Therapy, vol. 10, no. 8, pp. 1197–1208, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Kragballe, “Management of difficult to treat locations of psoriasis: scalp, face, flexures, palm/soles and nails,” Current Problems in Dermatology, vol. 38, pp. 160–171, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. D. McGonagle, N. Palmou Fontana, A. L. Tan, and M. Benjamin, “Nailing down the genetic and immunological basis for psoriatic disease,” Dermatology, vol. 221, supplement 1, pp. S15–S22, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. E. M. Griffiths, “Comparing biological therapies in psoriasis: implications for clinical practice,” Journal of the European Academy of Dermatology and Venereology, vol. 24, supplement 6, pp. S10–S14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. C. Prinz, “From bench to bedside—translational research in psoriasis,” Journal of the European Academy of Dermatology and Venereology, vol. 24, supplement 6, pp. S1–S4, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Quatresooz, T. Hermanns-Lê, G. E. Piérard, P. Humbert, P. Delvenne, and C. Piérard-Franchimont, “Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis. A primer,” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 147413, 5 pages, 2012. View at Publisher · View at Google Scholar
  7. A. Di Cesare, P. Di Meglio, and F. O. Nestle, “The IL-23Th17 axis in the immunopathogenesis of psoriasis,” Journal of Investigative Dermatology, vol. 129, no. 6, pp. 1339–1350, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Witowski, K. Ksiazek, and A. Jörres, “Interleukin-17: a mediator of inflammatory responses,” Cellular and Molecular Life Sciences, vol. 61, no. 5, pp. 567–579, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Watanabe, M. Kawaguchi, S. Fujishima et al., “Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis,” Journal of Investigative Dermatology, vol. 129, no. 3, pp. 650–656, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Pelletier, L. Maggi, A. Micheletti et al., “Evidence for a cross-talk between human neutrophils and Th17 cells,” Blood, vol. 115, no. 2, pp. 335–343, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Roussel, F. Houle, C. Chan et al., “IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation,” Journal of Immunology, vol. 184, no. 8, pp. 4531–4537, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. C. L. Leonardi, A. B. Kimball, K. A. Papp et al., “Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1),” The Lancet, vol. 371, no. 9625, pp. 1665–1674, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Daudén, D. Santiago-Et-Sánchez-Mateos, E. Sotomayor-López, and A. García-Díez, “Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis,” British Journal of Dermatology, vol. 163, no. 6, pp. 1346–1347, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. A. A. Pettey, R. Balkrishnan, S. R. Rapp, A. B. Fleischer, and S. R. Feldman, “Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice,” Journal of the American Academy of Dermatology, vol. 49, no. 2, pp. 271–275, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. A. M. Marsland, R. J. Chalmers, S. Hollis, J. Leonardi-Bee, and C. E. Griffiths, “Interventions for chronic palmoplantar pustulosis,” Cochrane Database of Systematic Reviews, vol. 1, Article ID CD001433, 2006. View at Scopus
  16. C. B. Livideanu, M. Lahfa, J. Mazereeuw-Hautier, and C. Paul, “Efficacy of ustekinumab in palmoplantar psoriasis,” Dermatology, vol. 221, no. 4, pp. 321–323, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Gerdes, J. Franke, S. Domm, and U. Mrowietz, “Ustekinumab in the treatment of palmoplantar pustulosis,” British Journal of Dermatology, vol. 163, no. 5, pp. 1116–1118, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Nuno-Gonzalez, E. Gomez de la Fuente, F. J. Vicente-Martin, and J. L. Lopez-Estebaranz, “Good response of hyperkeratotic palmoplantar psoriasis to ustekinumab,” Actas Dermosifiliografia, vol. 103, pp. 169–170, 2012.
  19. B. de Unamuno-Bustos, R. Balester-Sanchez, V. Oliver-Martinez, and V. Alegre de Miquel, “Ustekinumab for the treatment of palmar-plantar pustulosis,” Actas Dermosifiliografia, vol. 102, pp. 833–835, 2011.
  20. S. C. Au, A. M. Goldminz, N. Kim et al., “Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate to severe palmoplantar psoriasis,” Journal of Dermatological Treatment. In press.
  21. G. Safa, A. Martin, and L. Darrieux, “Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis,” Journal of Clinical Rheumatology, vol. 17, pp. 385–386, 2011.
  22. A. Kyriakou, A. Patsatsi, and D. Sotiriadis, “Detailed analysis of specific nail psoriasis features and their correlations with clinical parameters: a cross-sectional study,” Dermatology, vol. 223, pp. 222–229, 2011.
  23. C. Grover, B. S. Reddy, and C. K. Uma, “Diagnosis of nail psoriasis: importance of biopsy and histopathology,” British Journal of Dermatology, vol. 153, no. 6, pp. 1153–1158, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. M. M. Jiaravuthisan, D. Sasseville, R. B. Vender, F. Murphy, and C. Y. Muhn, “Psoriasis of the nail: anatomy, pathology, clinicalpresentation, and a review of the literature on therapy,” Journal of the American Academy of Dermatology, vol. 57, no. 1, pp. 1–27, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Augustin and A. Ogilvie, “Methods of outcomes measurement in nail psoriasis,” Dermatology, vol. 221, supplement 1, pp. 23–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. R. G. Langley and E. Daudén, “Treatment and management of psoriasis with nail involvement: a focus on biologic therapy,” Dermatology, vol. 221, supplement 1, pp. 29–42, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Williamson, N. Dalbeth, J. L. Dockerty, B. C. Gee, R. Weatherall, and B. P. Wordsworth, “Extended report: nail disease in psoriatic arthritis—clinically important, potentially treatable and often overlooked,” Rheumatology, vol. 43, no. 6, pp. 790–794, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. D. de Berker, “Management of psoriatic nail disease,” Seminars in Cutaneous Medicine and Surgery, vol. 28, no. 1, pp. 39–43, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. F. C. Wilson, M. Icen, C. S. Crowson, M. T. McEvoy, S. E. Gabriel, and H. M. Kremers, “Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study,” Arthritis and Rheumatism, vol. 61, no. 2, pp. 233–239, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. M. M. Jiaravuthisan, D. Sasseville, R. B. Vender, F. Murphy, and C. Y. Muhn, “Psoriasis of the nail: anatomy, pathology, clinicalpresentation, and a review of the literature on therapy,” Journal of the American Academy of Dermatology, vol. 57, no. 1, pp. 1–27, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. R. G. Langley, J. H. Saurat, and K. Reich, “Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus,” Journal of the European Academy of Dermatology and Venereology, vol. 26, pp. 373–381, 2012.
  32. G. E. Piérard, “Spores, sporodochia and fomites in onychomycosis,” Dermatology, vol. 213, no. 2, pp. 169–172, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. G. E. Piérard, P. Quatresooz, and J. E. Arrese, “Spotlight on nail histomycology,” Dermatologic Clinics, vol. 24, no. 3, pp. 371–374, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. E. M. de Jong, B. A. Seegers, M. K. Gulinck, J. B. Boezeman, and P. C. van de Kerkhof, “Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients,” Dermatology, vol. 193, no. 4, pp. 300–303, 1996. View at Scopus
  35. D. McGonagle, A. L. Tan, and M. Benjamin, “The nail as a musculoskeletal appendage—implications for an improved understanding of the link between psoriasis and arthritis,” Dermatology, vol. 218, no. 2, pp. 97–102, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Rich, C. Guzzo, Y. Wang, and K. Gordon, “Improvement in nail psoriasis with ustekinumab, a new anti-IL-12/23p40 monoclonal antibody: results from a phase 3 trial,” American Academy of Dermatology, Annual Meeting, 2008.
  37. P. Rich, R. Langley, C. Guzzo, et al., “Improvement in nail psoriasis with ustekinumab, a new anti-IL-12/23p40 monoclonal antibody: results from a pahse 3 trial (poster FP107),” 17th Congress EADV, Paris, France, 2008.
  38. E. Rallis, S. Kintzoglou, and C. Verros, “Ustekinumab for rapid treatment of nail psoriasis,” Archives of Dermatology, vol. 146, no. 11, pp. 1315–1316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Patsatsi, A. Kyriakou, and D. Sotiradis, “Ustekinumab in nail psoriasis : an open-label, uncontrolled, nonrandomized study,” Journal of Dermatological Treatment. In press.
  40. D. Rigopoulos, S. Gregoriou, M. Makris, and D. Ioannides, “Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis : an open prospective unblinded study,” Dermatology, vol. 223, pp. 325–329, 2011.
  41. L. Bianchi, A. Bergamin, C. de Felice, E. Capriotti, and S. Chimenti, “Remission and time of resolution of nail psoriasis during infliximab therapy,” Journal of the American Academy of Dermatology, vol. 52, no. 4, pp. 736–737, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Lawry, “Biological therapy and nail psoriasis,” Dermatology and Therapy, vol. 20, no. 1, pp. 60–67, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. F. van den Bosch, R. Reece, and F. Behrens, “Clinically important nail psoriasis improvements are achieved with adalimumab (Humira): results from a large open-label prospective study (STEREO),” Annals of Rheumatic Diseases, vol. 66, supplement 2, p. 421, 2007.
  44. P. Rich, C. E. Griffiths, K. Reich et al., “Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year,” Journal of the American Academy of Dermatology, vol. 58, no. 2, pp. 224–231, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Rigopoulos, S. Gregoriou, A. Stratigos et al., “Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study,” British Journal of Dermatology, vol. 159, no. 2, pp. 453–456, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Kragballe, “Management of difficult to treat locations of psoriasis: scalp, face, flexures, palm/soles and nails,” Current Problems in Dermatology, vol. 38, pp. 160–171, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Reich, “Approach to managing patients with nail psoriasis,” Journal of the European Academy of Dermatology and Venereology, vol. 23, supplement 1, pp. 15–21, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. R. G. Langley and E. Daudén, “Treatment and management of psoriasis with nail involvement: a focus on biologic therapy,” Dermatology, vol. 221, supplement 1, pp. 29–42, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Rigopoulos, S. Gregoriou, E. Lazaridou et al., “Treatment of nail psoriasis with adalimumab: an open label unblinded study,” Journal of the European Academy of Dermatology and Venereology, vol. 24, no. 5, pp. 530–534, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. D. de Berker, “Management of nail psoriasis,” Clinical and Experimental Dermatology, vol. 25, no. 5, pp. 357–362, 2000. View at Publisher · View at Google Scholar · View at Scopus
  51. R. L. Baran, “A nail psoriasis severity index,” British Journal of Dermatology, vol. 150, no. 3, pp. 568–569, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. S. P. Cannavò, F. Guarneri, M. Vaccaro, F. Borgia, and B. Guarneri, “Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study,” Dermatology, vol. 206, no. 2, pp. 153–156, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. J. P. Ortonne, R. Baran, M. Corvest, C. Schmitt, J. J. Voisard, and C. Taieb, “Development and validation of nail psoriasis quality of life scale (NPQ10),” Journal of the European Academy of Dermatology and Venereology, vol. 24, no. 1, pp. 22–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. N. Nikkels-Tassoudji, C. Pierard-Franchimont, P. De Doncker, and G. E. Pierard, “Optical profilometry of nail dystrophies,” Dermatology, vol. 190, no. 4, pp. 301–304, 1995. View at Scopus
  55. G. E. Piérard and C. Piérard-Franchimont, “Dynamics of psoriatic trachyonychia during low-dose cyclosporin A treatment: a pilot study on onychochronobiology using optical profilometry,” Dermatology, vol. 192, no. 2, pp. 116–119, 1996. View at Scopus
  56. C. Piérard-Franchimont and G. E. Piérard, “Surface image analysis of nail alterations in juvenile pityriasis rubra pilaris,” Skin Research and Technology, vol. 4, no. 1, pp. 34–36, 1998. View at Publisher · View at Google Scholar · View at Scopus
  57. G. E. Piérard, M. Caucanas, and C. Piérard-Franchimont, “Nail surface topography and onychochronobiology,” in Noninvasive diagnostic techniques in clinical dermatology, E. Berardesca, K. P. Wilhelm, and H. I. Maibach, Eds., Springer, Berlin, Germany, 2012.
  58. S. Z. Aydin, Z. Ash, F. Del Galdo et al., “Optical coherence tomography: a new tool to assess nail disease in psoriasis?” Dermatology, vol. 222, pp. 311–313, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. K. S. Stenn and R. Paus, “Controls of hair follicle cycling,” Physiological Reviews, vol. 81, no. 1, pp. 449–494, 2001. View at Scopus
  60. C. Piérard-Franchimont and G. E. Piérard, “Teloptosis, a turning point in hair shedding biorhythms,” Dermatology, vol. 203, no. 2, pp. 115–117, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Courtois, G. Loussouarn, C. Hourseau, and J. F. Grollier, “Hair cycle and alopecia,” Skin Pharmacology, vol. 7, no. 1-2, pp. 84–89, 1994. View at Scopus
  62. C. Piérard-Franchimont, L. Petit, G. Loussouarn, D. Saint-Léger, and G. E. Piérard, “The hair eclipse phenomenon: sharpening the focus on the hair cycle chronobiology,” International Journal of Cosmetic Science, vol. 25, no. 6, pp. 295–299, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. G. E. Piérard, C. Piérard-Franchimont, R. Marks, P. Elsner, and The EEMCO Group, “EEMCO guidance for the assessment of hair shedding and alopecia,” Skin Pharmacology and Physiology, vol. 17, no. 2, pp. 98–110, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. K. S. Kim, M. K. Shin, J. J. Ahn, C. R. Haw, and H. K. Park, “A comparative study of hair shafts in scalp psoriasis and seborrheic dermatitis using atomic force microscopy,” Skin Research and Technology. In press.
  65. M. K. Shin, K. S. Kim, J. J. Ahn, N. I. Kim, H. K. Park, and C. R. Haw, “Investigation of the hair of patients with scalp psoriasis using atomic force microscopy,” Clinical and Experimental Dermatology, vol. 37, pp. 156–163, 2012.
  66. A. Di Cesare, M. C. Fargnoli, and K. Peris, “Rapid response of scalp psoriasis to ustekinumab,” European Journal of Dermatology, vol. 21, pp. 993–994, 2011.
  67. C. S. Chan, A. S. Van Voorhees, M. G. Lebwohl et al., “Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation,” Journal of the American Academy of Dermatology, vol. 60, no. 6, pp. 962–971, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Bagel, C. Lynde, S. Tyring, G. Kricorian, Y. Shi, and P. Klekotka, “Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept,” Journal of the American Academy of Dermatology, vol. 67, pp. 86–92, 2012.
  69. C. L. Leonardi, A. B. Kimball, K. A. Papp et al., “Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1),” The Lancet, vol. 371, no. 9625, pp. 1665–1674, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. V. Ruiz Salas, L. Puig, and A. Alomar, “Ustekinumab in clinical practice: response depends on dose and previous treatment,” Journal of the European Academy of Dermatology and Venereology, vol. 26, pp. 506–513, 2012.